getimage-48-768x274.png
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 12, 2020 16:01 ET | Capricor Therapeutics
Exosome Platform Technology-Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19--Novel Vaccine Induced Long-Lasting Immunity to Multiple SARS-CoV-2...
getimage-48-768x274.png
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
November 09, 2020 09:15 ET | Capricor Therapeutics
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Scheduling Pre-IND Meeting with FDA...
getimage-48-768x274.png
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
November 05, 2020 09:00 ET | Capricor Therapeutics
LOS ANGELES, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based...
getimage-48-768x274.png
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
September 23, 2020 09:25 ET | Capricor Therapeutics
--Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage...
getimage-48-768x274.png
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 09:15 ET | Capricor Therapeutics
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and...
getimage-48-768x274.png
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
August 25, 2020 09:15 ET | Capricor Therapeutics
– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 – – The Study Leverages Capricor’s Lead Asset,...
getimage-48-768x274.png
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 06, 2020 16:01 ET | Capricor Therapeutics
Exosome Platform for COVID-19-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies--Preclinical Data Shows Positive Antibody Response- CAP-1002 for COVID-19-Expanded...
getimage-48-768x274.png
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
July 30, 2020 09:15 ET | Capricor Therapeutics
LOS ANGELES, July 30, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based...
getimage-48-768x274.png
Capricor to Participate in BIO Digital International Convention
June 04, 2020 09:15 ET | Capricor Therapeutics
Management to Host One-on-One Partnering Meetings Conference June 8-12, 2020 LOS ANGELES, June 04, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a...
getimage-48-768x274.png
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
May 26, 2020 09:25 ET | Capricor Therapeutics
LOS ANGELES, May 26, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological...